WeTrials
Recruiting

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

What is this study?

This study is testing a special medicine called volrustomig to see if it helps patients with locally advanced head and neck cancer. Researchers want to know if this immunotherapy drug works better at keeping the cancer away compared to just watching and waiting after standard treatments.

Who can participate?

You might be able to join if you have been diagnosed with head and neck cancer that cannot be removed by surgery and has not spread to distant parts of the body. You also need to have already finished a full round of combined chemotherapy and radiation treatment without your cancer getting worse.

What will happen?

Participants will either receive the volrustomig medicine or be placed in an observation group where doctors closely monitor your health. You will have regular check-ups with the study team to track your progress and check for any side effects.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in Alabama and Arizona. Your care team can help you find the most convenient location for your visits.

Key Points
  • 1Tests an immunotherapy drug called volrustomig for head and neck cancer
  • 2For patients who have already completed chemotherapy and radiation
  • 3Compares active treatment with the medicine against regular medical observation

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.